Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.

International journal of oncology - 1 Nov 2010

Luo Wentao, Wu Fan, Elmaoued Ruba, Beck Brandon B, Fischer Edgar, Meng Xiangbing, Leslie Kimberly K, Dai Donghai

Abstract excerpt

Endometrial cancer (ECa) is the fourth most common malignancy in women. Currently, there is no effective therapy for advanced and recurrent cancer. Among the poor-outcome endometrial cancers, there is a high frequency of TP53 mutations. We have previously reported that amifostine has a direct anti-cancer effect and has a significant synergistic effect with paclitaxel when used in endometrial cancer cell and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Separation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Endometrial Neoplasms

Share to Flow Cytometry

Share to Mice, Nude

Share to Paclitaxel

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 20878066
DOI: 10.3892/ijo_00000770

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.PMID 20878066Read ↗

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Semantic proximity Read ↗

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53Semantic proximity Read ↗

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.Semantic proximity Read ↗

Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 InhibitorSemantic proximity Read ↗

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial CancerSemantic proximity Read ↗

SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells.Semantic proximity Read ↗

Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas.Semantic proximity Read ↗

Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 <sup>WAF1/CIP1</sup>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.